Zoguri

Zoguri is a San Diego-based biotechnology company specializing in the development of small molecule therapies for metabolic and inflammatory disorders. The company's primary focus is on targeting G protein-coupled receptor 120 (GPR120), also known as FFAR4, which is a key regulator of metabolic health and systemic inflammation. Zoguri is advancing a pipeline of potent and selective GPR120 agonists designed to treat chronic conditions such as Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Type 2 Diabetes. Led by experienced industry veterans with backgrounds in metabolic drug development, the company aims to leverage natural fatty acid signaling pathways to restore metabolic balance. Their approach seeks to provide novel oral treatment options for patients with significant unmet needs in the hepatology and endocrinology spaces.